Category - News

Developments

NeuroSense posts positive results from stage 3 ALS biomarker study

NeuroSense Therapeutics (NASDAQ:NRSN) reported positive results from stage 3 of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense’s lead combination...

June 27, 2022

Markets

Cantor ups Aurora Cannabis to OW; PT up to $4.05 (Canadian)

Cantor Fitzgerald upgraded Aurora Cannabis (TSX:ACB) to “overweight” from “neutral” and raised its price target to $4.05 (Canadian) from $3.90. The stock closed at $1.84 on June 23. “We expect Europe, and more...

June 24, 2022

Markets

BTIG starts Akoya Biosciences at buy; PT $16

BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...

June 22, 2022

Developments

Zucara Therapeutics reports positive results from Phase 1b trial in T1D

Closely-held Zucara Therapeutics reported that its Phase 1b proof-of-concept trial demonstrated ZT-01’s ability to restore glucagon release in people with Type 1 diabetes. Data from 18 subjects that completed all three...

June 22, 2022

Markets

HCW starts Celularity at buy; PT $15

H.C. Wainwright initiated coverage of Celularity (NASDAQ:CELU) with a “buy” rating and $15 price target. The stock closed at $3.78 on June 21. Celularity is a clinical-stage biopharmaceutical company focused on...

June 22, 2022

Markets

Brookline ups Kymera Therapeutics PT to $93 from $80

Brookline Capital Markets raised its price target for Kymera Therapeutics (NASDAQ:KYMR) to $93 from $80 after the company dosed the first patients in separate Phase 1 studies for its KT-333 and KT-413 product candidates...

June 21, 2022

Developments

Hepion receives FDA orphan drug designation for rencofilstat in HCC

The FDA granted orphan drug designation to Hepion Pharmaceuticals’ (NASDAQ:HEPA) drug candidate, rencofilstat, a liver-targeting, orally administered, novel cyclophilin inhibitor, for the treatment of hepatocellular...

June 20, 2022

Markets

Maxim starts Medivir at buy; PT $3

Maxim Group initiated coverage of Sweden-based Medivir AB (OMX:MVIR-B) with a “buy” rating and $3 price target. The stock closed at 77 cents on June 16. Medivir is developing MIV-818 (fostrox), a prodrug of the...

June 17, 2022

Developments

FDA clears Rhythm Pharma’s IMCIVREE in Bardet-Biedl Syndrome

The FDA has approved Rhythm Pharmaceuticals’ (NASDAQ:RYTM) supplemental NDA for IMCIVREE (setmelanotide) for patients with Bardet-Biedl syndrome (BBS). IMCIVREE is indicated for chronic weight management in adult and...

June 17, 2022

Markets

Maxim starts ABVC BioPharma at buy; PT $3

Maxim Group initiated coverage of ABVC BioPharma (NASDAQ:ABVC) with a “buy” rating and price target of $3. The stock closed at 96 cents on June 16. ABVC is developing assets in ophthalmology, mental health, and oncology...

June 17, 2022

Category - News

Subscribe